SCHEMBL708734

SCHEMBL708734

O=C(OCC(Cl)Cl)N1C2CC3CC(C2)CC1C3

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.34
GPR119 Q8TDV5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699340 0.75 CHRM2 (0.38) HSD11B1
SCHEMBL27997362 0.74 HSD11B1 (0.33) HSD11B1
SCHEMBL3424501 0.69 CHRNB2 (0.50) HSD11B1
SCHEMBL699339 0.67 CHRM2 (0.37) HSD11B1
SCHEMBL708733 0.66 CHRM2 (0.46) HSD11B1
SCHEMBL17331177 0.65 HSD11B1 (0.40) HSD11B1
SCHEMBL19798467 0.64 CHRM2 (0.62) HSD11B1GPR119
SCHEMBL1923101 0.64
SCHEMBL7544991 0.62
SCHEMBL14783890 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423212-B1 PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND NISSAN CHEMICAL IND LTD (JP) 2016-06-01 EP disclosed
CN-102405221-B Process for production of 2-azaadamantane compound from bicyclocarbamate compound NISSAN CHEMICAL IND LTD 2015-01-21 CN disclosed
US-8329909-B2 Method for producing 2-azaadamantane compound from bicyclocarbamate compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-12-11 US disclosed
US-20120053348-A1 METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-01 US disclosed
EP-2423212-A1 PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2012-02-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053348-A1 METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND CNKSR1, HDAC11, HDAC1 HSD11B1 381/4885GPR119 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.